Ecnoglutide

Ecnoglutide (VRB-101) is a once-weekly GLP-1 receptor agonist that Verdiva Bio is developing as an oral tablet for obesity. Verdiva licensed Western rights (ex-Greater China and South Korea) to the molecule from Hangzhou Sciwind Biosciences in 2024 and launched January 9, 2025 with a $411M oversubscribed Series A co-led by Forbion and General Atlantic (with RA Capital, OrbiMed, Logos Capital, Lilly Asia Ventures, and LYFE Capital participating) to push it into the Western obesity market behind Novo Nordisk and Eli Lilly [9]. The lead Phase 2 trial (NCT07281937) completed August 2026 with topline readout expected Q4 2026 [4]. Sciwind retains rights in Greater China and South Korea, and in January 2026 won NMPA (China's FDA equivalent) approval for subcutaneous ecnoglutide in adult type 2 diabetes, followed by chronic weight management approval in March 2026 [16][17]. The pitch is simple: GLP-1 class efficacy with weekly oral dosing, differentiated against daily oral semaglutide (approved at full obesity doses December 2025) and injectable incumbents [10]. Whether the Western Phase 2 oral data support that pitch is what Q4 2026 will decide.

Ecnoglutide is not yet approved in any Western geography. Subcutaneous ecnoglutide is approved in China under Sciwind for adult type 2 diabetes (NMPA approval January 2026, based on Phase 3 EECOH-1 monotherapy and EECOH-2 metformin-combination trials) and for chronic weight management (NMPA approval March 2026, based on a Phase 3 obesity trial published in The Lancet Diabetes & Endocrinology showing 15.4% mean weight loss at the top dose at week 48) [16][17][18]. The Western lead program for the oral tablet sits in Phase 2 for obesity under Verdiva, with primary trial NCT07281937 completing August 2026 and readout expected Q4 2026 [4]. No FDA breakthrough, fast track, orphan, or priority review designations are publicly disclosed. A Phase 1 combination study pairing oral VRB-101 with the oral amylin analog VRB-103 (NCT07628127, n=332) is recruiting, which points to a combination strategy if monotherapy data warrant [5]. Sciwind is also advancing the molecule as XW003 in Chinese Phase 3 trials for knee osteoarthritis in obese adults (NCT07734311, n=360) and obstructive sleep apnea with and without positive airway pressure therapy (NCT07387094 and NCT07434050, n=140 each) [7][8][8b], plus a Phase 1b/2a oral tablet study in Chinese overweight and obese adults (NCT07243171, n=126) [6].

GLP-1 is a hormone the gut releases after you eat. It tells the pancreas to release insulin, slows how fast the stomach empties, and quiets hunger signals in the brain. The GLP-1 receptor is the switch these effects run through. Hit it, and the body behaves like it just finished a meal: full, insulin-responsive, satisfied. Semaglutide (Wegovy, Ozempic) from Novo Nordisk and tirzepatide (Mounjaro, Zepbound) from Eli Lilly have turned this into the most commercially proven mechanism in modern medicine, generating well over $40B in combined 2024 sales. Ecnoglutide is engineered for extended plasma half-life to support weekly dosing via two structural changes to the native GLP-1 peptide: an alanine-to-valine substitution at position 8 (which protects against degradation by the enzyme DPP-4) and conjugation of an 18-carbon fatty acid diacid at lysine 30 through a γGlu-2xAEEA linker, which binds plasma albumin and extends circulation time [18][19]. This is the same general strategy semaglutide uses (fatty acid albumin anchor), with a different attachment chemistry. Published pharmacology data show ecnoglutide is also 'cAMP-biased': it activates the cAMP signaling pathway potently while recruiting less β-arrestin, which reduces receptor internalization and desensitization [19]. The clean drug-drug interaction profile against rosuvastatin, digoxin, warfarin, and metformin means concurrent cardiovascular medications are unlikely to need dose adjustment [3][11]. The oral tablet is the technically harder bet, because peptides normally get destroyed by stomach acid before they can be absorbed (Novo's Rybelsus uses a permeation enhancer called SNAC). Verdiva has not publicly disclosed the oral formulation technology for VRB-101. Mechanistic validation is not the question. The question is whether this specific molecule, dosed orally once weekly, matches what the incumbents already deliver.

NCT07281937 is Verdiva's lead Phase 2 trial of weekly oral ecnoglutide in adults with obesity or overweight with weight-related comorbidities, completed August 2026 with topline results expected Q4 2026 [4]. Specific enrollment counts, dose arms, and the primary endpoint have not been widely disclosed in public communications, so a full design critique is limited. The standard Phase 2 obesity design in this class uses percent change in body weight at 24 or 52 weeks against placebo, with secondary endpoints covering the proportion of patients achieving 5%, 10%, and 15% weight loss. The sibling Chinese Phase 1b/2a (NCT07243171, n=126) is examining the oral tablet with safety and PK (pharmacokinetic - how the drug is absorbed, distributed, and cleared) endpoints [6]. The combination program NCT07628127 pairs oral ecnoglutide with oral VRB-103 (an amylin receptor-selective peptide analog targeting human amylin receptors AMY1R and AMY3R, a non-incretin appetite and gastric-emptying pathway complementary to GLP-1) across 332 participants in a SAD/MAD design that includes multiple VRB-101/VRB-103 dose ratios [5][20]. The combination hedges monotherapy risk and is mechanistically rational: pairing GLP-1 agonism with amylin agonism replicates the dual-hormone approach behind CagriSema (Novo's cagrilintide + semaglutide), which has shown weight loss above GLP-1 monotherapy in Phase 2. Chinese Phase 3 trials in osteoarthritis and sleep apnea use disease-specific endpoints (WOMAC pain score, a standardized knee pain and function questionnaire; and apnea-hypopnea index) rather than weight loss, which creates optionality for condition-specific labels [7][8][8b].

Our model estimates a 9% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 35%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is held back by the sponsor's thin or weak approval record, weak or limited earlier-phase results, heavier-than-usual blinding, and a randomized design. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is top of the list. 15 to 22% weight loss is the current bar: semaglutide delivers around 15%, tirzepatide around 22%, and the BMJ 2026 network meta-analysis of obesity drugs placed tirzepatide at the top of the ranking [2]. Ecnoglutide's Chinese subcutaneous Phase 3 obesity data (15.4% at top dose at 48 weeks) [18] and Chinese T2D data showing meaningful HbA1c (hemoglobin A1c, a three-month average blood sugar measure) reductions and class-standard GI tolerability [1][12] both land in the credible zone, but oral bioavailability of a weekly fatty-acid-conjugated peptide is a separate problem, and placebo-adjusted weight loss on a weekly oral formulation in a Western obesity population is unproven. Under 10% at the longest timepoint would make differentiation hard. Safety: class-wide risks remain in play, including GI side effects (nausea, vomiting, diarrhea), gallbladder events, pancreatitis, and the medullary thyroid carcinoma warning carried by all GLP-1 agonists on the basis of rodent data. No ecnoglutide-specific red flags have surfaced in the published PK and meta-analysis literature [1][3][11][12]. Execution risk: Verdiva is a Series A biotech with no commercial infrastructure, so the realistic exit is a Phase 3 handoff or acquisition, not an independent launch; Phase 3 obesity programs typically run $300-500M, which would require either another large financing round or a partnership. Commercial: oral semaglutide at obesity doses launched December 2025, resetting the convenience benchmark [10]. Orforglipron, Lilly's oral once-daily small molecule, is expected to file in 2026 [13]. By the time ecnoglutide reaches a Western Phase 3 readout, likely 2028 at the earliest, the market will have multiple approved oral GLP-1s and payers will pressure toward the cheapest adequate option. IP: ecnoglutide's composition-of-matter patents date to the mid-2010s (Sciwind), which likely leaves roughly a decade of exclusivity runway from launch, and formulation and combination patents can extend that, though specific expiry dates are not publicly indexed.

Watch, not chase. The signal to look for when NCT07281937 reads out in Q4 2026 is placebo-adjusted weight loss at the longest timepoint reported [4]. If it clears 12% at 52 weeks with class-standard GI tolerability, Verdiva has a legitimate Phase 3 asset and a plausible BD outcome. Pfizer, Roche, and AstraZeneca have all publicly committed to obesity and lack a Phase 3 oral GLP-1 of their own [14]. If the readout comes in under 8% or carries unusual tolerability signals, it is a pass. The commercial thesis rests entirely on whether weekly oral dosing produces meaningful compliance and persistence gains over daily oral semaglutide or weekly injectable alternatives, which is a real-world question that Phase 2 cannot answer directly. The second-order signal is Sciwind's China Phase 3 program in sleep apnea and osteoarthritis: positive data there supports disease-specific label strategies beyond pure obesity, where tirzepatide's SURMOUNT-OSA sleep apnea approval has already shown the playbook [15]. The third-order signal is VRB-103 Phase 1 readout: if the amylin monotherapy and the GLP-1/amylin combination both look clean, Verdiva's story moves from 'another oral GLP-1' to 'a dual-hormone oral platform' which materially changes the BD valuation. Check back when the NCT07281937 topline posts.